$1.05 Billion is the total value of Novo Holdings A/S's 22 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 41.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INGN | INOGEN INC | $238,408,000 | +12.1% | 3,549,320 | 0.0% | 22.70% | +20.2% | |
| VTI | Sell | VANGUARD INDEX FDStotal stk mkt | $187,176,000 | -22.0% | 1,623,100 | -24.7% | 17.83% | -16.3% |
| CLCD | COLUCID PHARMACEUTICALS INC | $114,899,000 | -4.6% | 3,156,563 | 0.0% | 10.94% | +2.3% | |
| VGK | VANGUARD INTL EQUITY INDEX Fftse europe etf | $100,722,000 | -1.6% | 2,101,000 | 0.0% | 9.59% | +5.5% | |
| RETA | REATA PHARMACEUTICALS INCcl a | $73,518,000 | -17.2% | 3,367,763 | 0.0% | 7.00% | -11.2% | |
| IRTC | New | IRHYTHM TECHNOLOGIES INC | $60,733,000 | – | 2,024,448 | +100.0% | 5.78% | – |
| CRVS | CORVUS PHARMACEUTICALS INC | $46,104,000 | -13.1% | 3,224,046 | 0.0% | 4.39% | -6.8% | |
| XLRN | Buy | ACCELERON PHARMA INC | $31,649,000 | -3.2% | 1,240,173 | +37.2% | 3.01% | +3.8% |
| RARX | New | RA PHARMACEUTICALS INC | $30,859,000 | – | 2,031,562 | +100.0% | 2.94% | – |
| MRUS | MERUS N V | $29,774,000 | +26.0% | 1,410,417 | 0.0% | 2.84% | +35.2% | |
| SPNC | Buy | SPECTRANETICS CORP | $28,889,000 | -0.4% | 1,179,122 | +2.0% | 2.75% | +6.8% |
| FLXN | Buy | FLEXION THERAPEUTICS INC | $26,585,000 | +23.9% | 1,397,718 | +27.3% | 2.53% | +32.9% |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $20,517,000 | – | 2,901,927 | +100.0% | 1.95% | – |
| APEN | New | APOLLO ENDOSURGERY INC | $17,716,000 | – | 1,456,972 | +100.0% | 1.69% | – |
| NBRV | Buy | NABRIVA THERAPEUTICS AG | $13,866,000 | +76.1% | 2,326,544 | +108.3% | 1.32% | +89.0% |
| IVTY | Buy | INVUITY INC | $7,581,000 | -57.0% | 1,318,448 | +2.6% | 0.72% | -53.9% |
| DERM | New | DERMIRA INC | $6,568,000 | – | 216,562 | +100.0% | 0.62% | – |
| WMGIZ | WRIGHT MED GROUP N Vright 03/01/2019 | $6,101,000 | +0.8% | 4,622,032 | 0.0% | 0.58% | +8.0% | |
| CRSP | New | CRISPR THERAPEUTICS AGnamen akt | $4,524,000 | – | 223,317 | +100.0% | 0.43% | – |
| HTGM | HTG MOLECULAR DIAGNOSTICS INC | $2,868,000 | -1.3% | 1,280,185 | 0.0% | 0.27% | +5.8% | |
| XENE | XENON PHARMACEUTICALS INC | $982,000 | -4.9% | 127,563 | 0.0% | 0.09% | +2.2% | |
| OPK | OPKO HEALTH INC | $2,000 | -33.3% | 259 | 0.0% | 0.00% | – | |
| OPHT | Exit | OPHTHOTECH CORP | $0 | – | -3,610,487 | -100.0% | -14.79% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VANGUARD INDEX FDS | 41 | Q3 2022 | 64.7% |
| INOGEN INC | 34 | Q2 2022 | 68.8% |
| VANGUARD INTL EQUITY INDEX F | 29 | Q4 2016 | 37.6% |
| AMICUS THERAPEUTICS INC | 22 | Q3 2023 | 4.1% |
| AKEBIA THERAPEUTICS INC | 21 | Q3 2020 | 4.8% |
| VERONA PHARMA PLC | 21 | Q2 2022 | 1.9% |
| CORVUS PHARMACEUTICALS INC | 20 | Q4 2020 | 7.1% |
| INSPIRE MED SYS INC | 20 | Q3 2023 | 1.8% |
| CABLE ONE INC | 19 | Q3 2023 | 9.7% |
| FLEXION THERAPEUTICS INC | 19 | Q3 2021 | 4.7% |
View Novo Holdings A/S's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyteir Therapeutics, Inc. | August 03, 2023 | 1,547,136 | 4.4% |
| Disc Medicine, Inc. | June 28, 2023 | 1,090,772 | 4.8% |
| Galera Therapeutics, Inc. | June 28, 2023 | 2,100,000 | 4.9% |
| VectivBio Holding AGSold out | May 26, 2023 | 0 | 0.0% |
| LanzaTech Global, Inc. | February 17, 2023 | 15,814,845 | 8.1% |
| Bolt Biotherapeutics, Inc.Sold out | January 04, 2023 | 0 | 0.0% |
| Arcellx, Inc. | December 12, 2022 | 1,750,000 | 4.0% |
| MINERVA SURGICAL INC | November 03, 2022 | 1,322,473 | 4.5% |
| Milestone Pharmaceuticals Inc. | October 24, 2022 | 1,378,538 | 4.6% |
| Galecto, Inc. | September 30, 2022 | 2,497,791 | 9.8% |
View Novo Holdings A/S's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 144 | 2024-03-18 |
| 4 | 2024-03-18 |
| SC 13D/A | 2024-03-18 |
| 144 | 2024-03-14 |
| SC 13D/A | 2024-03-07 |
View Novo Holdings A/S's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.